Search Results
Your search for early matches 10012 pages
Showing 1901 - 1950Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Expert Point of View: Joseph Mikhael, MD
The ASCO Post asked Joseph Mikhael, MD, Chief Medical Officer of the International Myeloma Foundation and Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (an affiliate of City of Hope Cancer Center), to comment on the GMMG-HD7...
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
Expert Point of View: Laurie H. Sehn, MD, MPH
The moderator of the session, Laurie H. Sehn, MD, MPH, Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, called the results of the TRANSFORM trial “quite remarkable” and said chimeric antigen receptor (CAR) T-cell therapy has the...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
Expert Point of View: Laurie H. Sehn, MD, MPH and Alex Herrera, MD
Laurie H. Sehn, MD, MPH, Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, and Alex Herrera, MD, Associate Professor in Hematology and Hematopoietic Cell Transplantation at the Beckman Research Institute of City of Hope,...
ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL
Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Do AYA Cancer Survivors Face a Higher Risk of Developing and Dying From a New Primary Cancer?
New findings published by Hyuna Sung, PhD, and colleagues in the Journal of the National Cancer Institute showed that 5-year survivors of adolescent and young adult (AYA) cancer in the United States have a higher risk of developing—and nearly double the risk of dying from—a new primary cancer,...
Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer
Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...
Study Finds Long-Term Increase in Cancer Risk After High Childhood BMI
Men who had a high body mass index (BMI) as children are at an elevated risk of obesity-related cancer later in life, even if their weight was normal in young adulthood, according to a new study from researchers at the University of Gothenburg, Sweden. Célind et al published their findings in the...
Cancer Rates Declining in Canada, but Cases and Deaths Increasing Because of Demographic Factors
Overall cancer rates in Canada are declining, but the number of cases and deaths are increasing slightly because of population growth and an aging population, according to a new study published by Brenner et al in CMAJ (Canadian Medical Association Journal). The study is the result of a...
Study Identifies Genetic Changes in Patients With Barrett’s Esophagus That Progresses to Esophageal Cancer
Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett’s esophagus compared to patients whose Barrett’s progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops....
Increased Risk of Cancer in Early Life Among Individuals With Autism Spectrum Disorders
In the largest and most detailed population-based cohort study to date, researchers from the Karolinska Institute in Stockholm found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early...
Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer
In a study reported in JAMA Surgery, Hanson et al found no difference in long-term satisfaction with breasts among women with early breast cancer who underwent breast-conserving surgery with radiation therapy vs mastectomy and breast reconstruction without radiation therapy. Women who underwent...
How to Get the Dose Right
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mirat Shah, MD, of the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA; Atiqur...
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response defects....
From Iran to Silicon Valley, a Cancer Survivor Shares Her Story
The Iranian revolution of 1979 transformed Iran from an absolute monarchy under Shah Mohammad Pahlavi to an Islamist republic under Ayatollah Khomeini. The author of a new book called The Magic of Normal, Maky Zanganeh, PhD, was born in Iran in 1970. As a young woman, she experienced the war in her ...
Immunotherapy in B-Cell Non-Hodgkin Lymphomas: Off-the-Shelf Bispecific Antibodies
Chimeric antigen receptor (CAR) T-cell therapies are a significant advance, but they require careful patient selection, dependency on patients’ own T cells, lymphodepleting chemotherapy, possible bridging therapy, manufacturing timelines with extensive health-care coordination and cost, in...
Incidental Findings on Low-Dose CT Lung Cancer Screening in the NLST and Risk of Respiratory Disease Mortality
In an analysis of data from the National Lung Screening Trial (NLST) reported in Chest, Paul F. Pinsky, PhD, of the Division of Cancer Prevention, National Cancer Institute, and colleagues found that incidental respiratory disease–related findings on low-dose computed tomography (CT) screening...
IDH1/2 Inhibitors Show Activity in Patients With Myelodysplastic Syndrome
The oral targeted small-molecule inhibitors of mutant IDH1 and IDH2 appear to be active in patients with myelodysplastic syndrome (MDS) harboring these mutations, according to two phase II trials by the Groupe Francophone des Myélodysplasies (GFM) and its German colleagues in the European MDS...
Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for Triple-Negative Breast Cancer: The Paradigm Shifts
The “holy grail” of triple-negative breast cancer therapy has been effective incorporation of drugs to improve outcomes in the early nonmetastatic setting. Although outcomes have improved with better chemotherapy drugs and schedules, triple-negative breast cancer still carries the worst prognosis...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...
Clinical Trials Updates in the Treatment of Older Adults With Gastrointestinal Malignancies
The theme of the 2022 ASCO Gastrointestinal Cancers Symposium was “Accelerating Access to Precision Care Through Innovation.” Several studies presented at this meeting focused on older patients, who represent the majority of patients with gastrointestinal malignancies. Data reviewed at the meeting...
Expert Point of View: Angela DeMichele, MD, MSCE
Abstract discussant, Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania, Philadelphia, complimented the study design and conduct of the ABC trial while exploring several possible...
Phase III Trial Evaluates the Role of Aspirin in Preventing Breast Cancer Recurrence
Taking aspirin daily does not prevent breast cancer recurrence, according to research presented during the February ASCO Plenary Series Program.1 Results of the double-blind phase III study of more than 3,000 patients with high-risk, HER2-negative breast cancer showed no improvement in invasive...
Expert Point of View: Martin Reck, MD, PhD
The discussant of the PEARLS/KEYNOTE-091 trial, Martin Reck, MD, PhD, underscored the need to do more in the perioperative management of patients with early-stage non–small cell lung cancer (NSCLC) to improve rates of overall survival and relapse after surgery. Dr. Reck is Head of the Department of ...
Study Reports Adjuvant Pembrolizumab Improves Disease-Free Survival in Early-Stage NSCLC
Adjuvant pembrolizumab improves disease-free survival compared with placebo in patients with early-stage non–small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy when indicated. These findings from the PEARLS/KEYNOTE-091 trial were reported in a European Society for ...
Selinexor Improves Progression-Free Survival in Endometrial Cancer
In the treatment of advanced endometrial cancer, maintenance therapy with oral selinexor after response to first-line chemotherapy may result in a significantly reduced risk of disease progression, according to the results of the global phase III ENGOT-EN5/GOG-3055/SIENDO trial, presented at the...
Is Neoadjuvant Pembrolizumab Underused in the Treatment of Early-Stage Triple-Negative Breast Cancer?
Neoadjuvant pembrolizumab has been approved in combination with chemotherapy for high-risk, early-stage, triple-negative breast cancer, but not all patients with node-positive disease have been able to receive the regimen, according to data presented during the Society of Surgical Oncology 2022...
Phase III Trials and Tribulations
Imagine this. You are a large pharmaceutical company that launches an international randomized phase III trial to assess whether one of your drugs improves the outcome of patients with a common type of cancer. The trial was solidly backed by preclinical evidence that the drug target was essential ...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
As reported in The New England Journal of Medicine by Forde et al, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based chemotherapy in the neoadjuvant treatment of resectable non–small cell...
Internal Mammary Node Irradiation in Node-Positive Early Breast Cancer: 15-Year Outcomes
As reported in the Journal of Clinical Oncology by Thorsen et al, 15-year follow-up of the Danish Breast Cancer Group Internal Mammary Node study indicates continued survival benefit with internal mammary node irradiation in women with right breast tumors vs without such therapy in those with left...
Role of 21-Gene Recurrence Score and Preoperative Endocrine Therapy Response in Guiding Treatment in Early Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a German trial (WSG-ADAPT-HR1/HER2–) reported in the Journal of Clinical Oncology, Nitz et al found no difference in invasive disease-free survival between women with early hormone receptor–positive, HER2-negative breast cancer with zero to three positive nodes who had a 21-gene recurrence score ...
Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy
Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or...
Study Shows Pemigatinib Activity in Treatment of Myeloid or Lymphoid Neoplasms With FGFR1 Rearrangement
In patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements, pemigatinib produced high and durable response rates, despite patients’ extensive use of prior treatments or hematopoietic stem cell transplantation (HSCT), according to the early results of the multicenter phase II FIGHT-203 ...
Association of Preexisting Thyroid Autoimmunity With Risk of Papillary Thyroid Cancer
In a case-control study among U.S. active-duty personnel reported in the Journal of Clinical Oncology, McLeod et al found that preexisting thyroid autoimmunity was associated with an increased risk of developing papillary thyroid cancer. The study included 451 randomly selected personnel serving...
Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates
Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, discusses the various agents available to treat patients with indolent B-cell lymphomas: lenalidomide plus rituximab, which has a superior progression-free survival profile compared with rituximab monotherapy; the PI3K inhibitors copanlisib ...
Effect of Changes to California Medicaid Dental Benefits on Earlier Diagnosis of Oral Cavity Cancer
In a study reported in a research letter in JAMA Oncology, Kana et al found that changes to Medicaid dental benefits in California from comprehensive to emergency services—and then back to comprehensive—were associated with reduced, then increased, percentages of cases of oral cavity cancer...
Therapies Targeting DNA Damage Response Show Antitumor Activity
Results from two early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—the ATR inhibitor elimusertib and the PARP inhibitor AZD5305—are safe and clinically beneficial in treating patients with advanced solid tumors. Principal investigator Timothy...
Association Between Venous Thromboembolism Risk and Blood Type
A new study published by Englisch et al in the journal Blood Advances suggests that people with cancer and non-O blood types—such as types A, B, and AB—may face an increased risk of developing venous thromboembolism (VTE) 3 months after their initial diagnosis. Scientists have long strived to...
In the Neoadjuvant Setting, Combination Immunotherapy With Durvalumab Is More Effective Than Durvalumab Alone for Early-Stage NSCLC
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to research presented by Cascone et al at the American Association for Cancer...
New CAR T-Cell Therapy for Solid Tumors Was Safe and Showed Early Efficacy
A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented by Haanen et al...
FDA Issues New Draft Guidance to Industry for Developing Plans to Enroll Participants From Underrepresented Racial and Ethnic Populations
Recently, the U.S. Food and Drug Administration (FDA) issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the United States into clinical trials—expanding on the agency’s previous guidances for industry to...
Meenakshi Anurag, PhD, on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant
Meenakshi Anurag, PhD, of Baylor College of Medicine, discusses results from the ALTERNATE trial, which showed the combination of anastrozole plus fulvestrant was superior to either drug alone in inhibiting tumor proliferation in postmenopausal women with early-stage luminal B breast cancer...
Tina Cascone, MD, PhD, on NSCLC: New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy
Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the findings of the phase II NeoCOAST study, which showed that combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents resulted in numerically higher major pathologic...
Klaus Pantel, MD, on Liquid Biopsy Research: Opportunities and Challenges
Klaus Pantel, MD, of the University Medical Center Hamburg-Eppendorf, discusses liquid biopsy technologies and biomarkers, with a focus on circulating tumor cells and circulating tumor DNA; clinical applications such as early detection of cancer, improved staging, and surveillance of measurable...
An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records
An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within 3 to 36 months, according to results presented by Placido et al at the American...
John B.A.G. Haanen, MD, PhD, on Solid Tumors: Early Study Results on CAR T Cells and the CARVac Vaccine Strategy
John B.A.G. Haanen, MD, PhD, of the Netherlands Cancer Institute, discusses findings from a phase I study designed to test the safety and efficacy of the CARVac (CAR-T cell-amplifying RNA vaccine) strategy to overcome poor CAR T-cell stimulation and responses in patients with CLDN6-positive...
Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act of 1971
Recently, I had the honor of coauthoring a chapter with Eric P. Winer, MD, President-Elect of ASCO, on the evolution of clinical cancer care since the enactment of the National Care Act of 1971 for the book A New Deal for Cancer: Lessons From a 50-Year War, by Abbe R. Gluck and Charles S. Fuchs,...
